TY - JOUR T1 - Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 41 LP - 49 DO - 10.2967/jnumed.118.214684 VL - 60 IS - 1 AU - Kaveh Zakeri AU - Deepa Narayanan AU - Greg Evans AU - Pataje Prasanna AU - Jeffrey C. Buchsbaum AU - Bhadrasain Vikram AU - Jacek Capala Y1 - 2019/01/01 UR - http://jnm.snmjournals.org/content/60/1/41.abstract N2 - The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them. ER -